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Abstract 
The dimorphic fungus Candida albicans produces extracellular farnesol (3,7, 11-tri-
methyl-2,6,10-dodecatriene- 1-ol) which acts as a quorum-sensing molecule (QSM) 
to suppress filamentation. Of four possible geometric isomers of farnesol, only the 
E,E isomer possesses QSM activity. We tested 40 natural and synthetic analogs of 
farnesol for their activity in an N-acetylglucosamine-induced differentiation assay 
for germ tube formation (GTF). Modified structural features include the head group, 
chain length, presence or absence of the three double bonds, substitution of a back-
bone carbon by S, O, N, and Se heteroatoms, presence or absence of a 3-methyl 
branch, and the bulkiness of the hydrophobic tail. Of the 40 compounds, 22 showed 
QSM activity by their ability to reduce GTF by 50%. However, even the most active 
of the analogs tested had only 7.3% of the activity of E,E-farnesol. Structure-activ-
ity relationships were examined in terms of the likely presence in C. albicans of a 
farnesol binding receptor protein. 
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Introduction 
The dimorphic fungus Candida albicans is the first eukaryotic system 
shown to possess quorum-sensing behavior [1]. Quorum sensing has 
been thoroughly described in prokaryotes but had not been demon-
strated in eukaryotes until recently. With this phenomenon, a secreted 
compound accumulates to a critical concentration in the medium 
and then acts back on the producing cells to elicit a physiological re-
sponse. For Gram-negative bacteria, the quorum-sensing molecules 
are all members of a family of compounds known as acyl homoser-
ine lactones [2]. In the case of C. albicans, the quorum-sensing mole-
cule (QSM) is the sesquiterpene farnesol (3,7,11-trimethyl-2,6,10-do-
decatriene-1-ol). Accumulation of farnesol blocks the morphological 
shift from yeasts to mycelia [1]. Farnesol blocks germ tube formation 
as triggered by serum, proline, or N-acetylglucosamine, and it is pro-
duced by and active on all (five) strains of C. albicans tested [1]. 
The effect of farnesol concerned morphological choice, not growth 
rate. At concentrations of up to 250 μM, farnesol did not alter the 
growth rate for C. albicans; actively budding yeasts were observed 
in all cases [1]. This finding was confirmed by Ramage et al. [3] who 
observed unimpaired growth rates up to 300 μM farnesol. The yeast-
mycelia transition is critical for pathogenicity, and C. albicans mu-
tants limited to the yeast morphology are avirulent [4]. A follow-up 
question based on this discovery is to identify farnesol’s mode of ac-
tion in blocking germ-tube formation in C. albicans. One way of ap-
proaching this question is to design, prepare, and assay analogs of 
farnesol with the expectation that comparison of the activity profiles 
would identify essential and extraneous structural features. There is 
also the possibility of synthesizing a compound with greater activ-
ity than that of farnesol. Analogs with enhanced activity could prove 
useful in a clinical setting for prevention or prophylaxis of Candidia-
sis. This study looks at a series of first generation analogs of farnesol 
and begins to uncover the biology of the quorum-sensing response 
in Candida albicans as mediated by farnesol. To date, we have ana-
lyzed 40 analogs of farnesol. Of these, 22 show activity as determined 
by their ability to reduce germ tube formation by at least 50% at con-
centrations up to 100 μM. 
As well as gaining a better understanding of the biology of fun-
gal quorum sensing, there are at least four practical advantages to 
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be gained from farnesol analogs. (1) Preliminary experiments with 
a mouse model show no obvious toxicity from farnesol. However, if 
farnesol toxicity were to become a problem at higher dosages or with 
prolonged treatment, it would be desirable to develop less toxic an-
alogs that still maintain QSM activity. (2) Farnesol has limited water 
solubility. Modifications of the structure of farnesol might lead to ac-
tive compounds that were more soluble and thus more easily deliv-
erable in animal systems. (3) Analogs of farnesol might also possess 
improved pharmacokinetics, such as an enhanced ability to enter the 
blood stream via the gastrointestinal tract or peritoneum. Alterna-
tively, since farnesol is usually excreted from animals after its con-
version to farnesoic acid and dicarboxylic acids [5], specific structural 
changes may improve retention. Both scenarios could help maintain 
the analog in an available form in the host. (4) While our in vitro stud-
ies suggest a possible prophylactic use for farnesol, it is still unclear 
whether this will be seen in an animal model. Farnesol could prove to 
act as a virulence factor for C. albicans. This question was posed by 
Hornby et al. [1] based upon anticipated differences between in vitro 
studies performed in a glass vessel and in vivo studies, where cellu-
lar membranes might act as a sink for the lipophilic farnesol. If farne-
sol functions as a virulence factor for C. albicans, it would be impor-
tant to develop farnesol analogs that act as antagonists of virulence. 
Results 
Our previous work [1] reported that both commercial mixed isomers 
farnesol and 96% E,E-farnesol exhibited QSM activity. However, sub-
sequent comparisons with freshly opened bottles of farnesol showed 
significantly greater activity with the E,E isomer (Table 1) and dif-
fering activities with mixed isomers farnesol from different suppli-
ers (Table 1). Ninety-six percent E,E-farnesol reduced GTF to fifty per-
cent at 1.2 μM, with complete inhibition at ca. 7.5 μM (Table 1) while 
mixed isomers farnesol from Sigma (St Louis, MO) and Acros Organ-
ics (Pittsburgh, PAl reduced germ tube formation (GTF) to 50% at ca. 
3.5 and 4.4 μM, respectively (Table 1). The three farnesol samples were 
therefore analyzed by GCI MS. The lower activity Acros mixed isomers 
farnesol contained only 33%-36% E,E-farnesol, whereas the higher ac-
tivity Sigma mixed isomers farnesol contained 56% E,E-farnesol (Table 
Shchep in ,  Hornby  et  al .  in  Chemistry  &  B iology  10  (2003 )       4
1). There was sufficient E,E-farnesol in the two mixed isomers samples 
to account for their QSM activities (Table 1). Based upon the percent-
age of E,E-farnesol in the Sigma and Acros Organics samples, reduc-
tion to 50% GTF would have been expected to occur at concentra-
tions of 2.1 and 3.2 μM, respectively (Table 1). These concentrations 
are lower than those determined experimentally for the mixed isomers 
samples. Thus, it appears that only E,E-farnesol possesses QSM activ-
ity, and furthermore, a comparison of observed QSM activity (Table 
1) with that predicted by the E,E-farnesol content suggests the other 
isomers may even act to inhibit QSM activity. 
Head Group Modifications 
We tested six farnesol analogs with altered head groups (Table 2). 
These modifications were introduced to learn whether farnesol’s C-1 
hydroxyl was essential for QSM activity. An analog was considered to 
be active if it was capable of reducing GTF by 50% at concentrations 
of ≤100 μM. In practice, this definition meant that analogs were con-
sidered active if they had ≥1 % of the activity of E,E-farnesol. Farne-
soic acid (analog 2, 3.3% relative activity) and the corresponding am-
ide (3, 1.9%) maintained biological activity, whereas the aldehyde (4, 
0.4%), bromide (5, 0.7%), methyl ester (6, 0.1 %), and amine (7, 0.1%) 
were inactive (Table 2). The sulfhydryl analog was too insoluble to be 
bioassayed. In particular, farnesoic acid, which has also been identi-
fied as a QSM produced by C. albicans [6], displayed only 3.3% of the 
Table 1. QSM Activity of Three Commercial Samples of Farnesol
    Calculated 
    Concentration 
  Concentration Concentration (μM) for 50% GTF 
 Percent (μM) for (μM) for Based on Percent 
Farnesol Source E,E-Farnesola 0% GTFb 50% GTFb E,E-Farnesolc
Sigma E,E-farnesol  96  7.5  1.2  1.2
Sigma mixed isomers  56  25  3.5  2.1
Across mixed isomers  36  30  4.4  3.2
a. Determined by GC/MS as previously described [1].
b. Based on the regression analysis as described in Experimental Procedures.
c. Calculated values of concentration that would be needed if all observed activity were due 
to E,E-farnesol only, based on the known E,E-farnesol content of each sample.
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activity exhibited by farnesol (Table 2). With regard to farnesol’s mode 
of action, it is significant that the hydroxyl head group is not essen-
tial for QSM activity (Table 2). This conclusion is supported by the ob-
servation of Matsuoka and Oh that β-farnesene, with no functional 
groups whatsoever, retained QSM activity [7]. 
Double Bond Modifications 
We next examined five analogs based upon alterations of the 2,3 dou-
ble bond in farnesol (Table 3). The 2,3 cyclopropane ring analog (8, 
3.3%) maintained biological activity, whereas the 2,3 epoxide (9, 0.4%) 
and 2,3 hydrogenated (10, 0.4%) analogs were inactive (Table 3). The 
terminal 10,11 double bond was also essential for activity in that the 
10,11 hydrogenated (11, 0.3%) and fully hydrogenated (12, 0.3%) an-
alogs were inactive (Table 3). Not unexpectedly, all-trans retinol (vi-
tamin A), a farnesol analog with five conjugated double bonds and a 
bulky, cyclic tail group was also inactive (data not shown). 
Sulfur-Containing Analogs 
We next tested a series of 14 analogs that incorporated sulfur atoms in 
place of a main chain CH2 unit (Tables 4 & 5). Seven of the eight ana-
logs with a sulfur in the 4 position retained QSM activity (Table 4) in-
cluding both the E- and Z- isomers of 4-thia farnesol (13, 3.7% and 14, 
3.4%, respectively). Surprisingly, the 2,3 hydrogenated 4-thia analog 
Table 2. Biological Activity of Farnesol Analogs Based on Modified Head Groups 
Analog    Relative 
Number  X =  IC50 (μM)a  Activity 
1  CH2OH (Farnesol)  1.2  100.0 
2  COOH (Famesoic Acid)  36.2  3.26 
3  CONH2  62.3  1.89 
4  CHO (Farnesal)   0.38 
5  CH2Br (Commercial E,E)   0.75 
6  COOCH3   0.10 
7  CH2NH2   0.14 
a. Inhibitory concentration (μM) at which germ tube formation is reduced to 50%.
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(15, 7.3%) retained activity (Table 4), to the extent that it was ca. 16-
fold more active than the 2,3 hydrogenated analog (10) offarnesol it-
self (Table 3). The importance of the proximal 3-methyl side chain in 
the 4-thia series was examined (Table 4) via comparison of the methyl-
ated compound 15 with the demethylated series represented by com-
pounds 16 (3.7%), 17 (1.5%), and 18 (1.7%). All three demethyl ana-
logs retained activity, as did the 3,4 disulfide (19, 1.6%). We can then 
make the comparison among three compounds (17, 15, and 20 [0.5%]) 
with increasingly bulky 3-side chains (Table 4); activity increases 5-fold 
with insertion of the 3-methyl (15 versus 17) and then decreases 16- 
fold with the bulkier 3-ethyl (20 versus 15). 
Similarly, five of the six analogs with the sulfur atom in the 9 posi-
tion also retained QSM activity (Table 5). The 9-thia series with n-butyl 
(21, 4.9%), isobutyl (22, 2.6%), and t-butyl (23, 0.9%) showed decreas-
ing activity with increased branching (Table 5). The relative inactivity 
of the t-butyI9-thia analog (23) should not be due merely to greater 
hydrophobicity because the n-pentyl (24, 1.8%), benzyl (25, 1.7%), and 
Table 3. Biological Activity of Farnesol Analogs Based on Modifications to Their 2,3 Dou-
ble Bond
Analog  Double Bond    Relative
Number  Modification  IC50 (μM)  Activity
1  None  1.2  100.0
8  2,3-cyclopropane  35.9  3.26
9  2,3-epoxide   0.38
10  2,3-hydrogenated   0.45
11  10,11-hydrogenated   0.31
12  Hydrogenate all three double bonds   0.31
 X =
27   68.7  1.72
28   23.2  5.08
29   24.4  4.80
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phenyl (26, 1.5%) 9-thia analogs still had QSM activity (Table 5). How-
ever, it could reflect the bulkier cross-section of the t-butyl being un-
able to fit into the narrow cleft of a farnesol receptor. 
Chain Length Modifications 
Farnesol is a 15 carbon sesquiterpene; it has a 12 carbon chain with 
three methyl branches. We next examined whether altering the chain 
length alters QSM activity. Three demethylated, 2,3-hydrogenated an-
alogs (27, 1.7%; 28, 5.1%; and 29, 4.8%) have chain lengths of 10-12 
carbons (Table 3) and lack the 2,3 double bond and 3-methyl branch 
Table 4. Biological Activity of Farnesol Analogs with Sulfur Atoms at the 4 Position
Analog     Relative
Number  X =   IC50 (μM)  Activity
13   (trans)  32.1  3.67
14   (cis)  35.1  3.36
15    16.0  7.34
16    31.6  3.70
17    79.1  1.47
18    67.0  1.75
19   (disulfide)  72.4  1.61
20     0.48
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found in farnesol. Compounds 27-29 all exhibited activity, suggesting 
some flexibility with regard to chain lengths. This flexibility with regard 
to chain length was also shown by the 4-thia (Table 4) and 9-thia (Ta-
ble 5) analogs. Counting S and –CH2– as equivalent, compounds 16-
18 in the 4-thia series (with chain lengths of 11-13, respectively) all 
had QSM activity (Table 4) as did compounds 21 and 24 in the 9-thia 
series (with chain lengths of 13-14, Table 5). 
Heteroatoms in the Carbon Chain 
Based on our success with the sulfur-containing analogs (Tables 4 and 
5), we tried a series of other heteroatoms at the 4 and 9 positions (Ta-
ble 6). The 4-Se analog (30, 2.6%) was the only one which retained 
QSM activity; all the O-containing analogs and the one N-containing 
analog (31,0.03%) were inactive (Table 6). In each case, the oxygen-
containing analog was less active than the corresponding sulfur-con-
taining analog. Compound 32 (0.1%) was 21-fold less active than 17, 
compound 33 (0.5%) was 14-fold less active than 15, compound 34 
(0.4%) was 4.6-fold less active than 18, and compound 35 (1.0%) was 
2.8-fold less active than 22. 
Hydroxyl and Epoxide Analogs of Farnesol 
As seen in Table 3, the epoxide at the 2,3 position (9) was ca. 260-fold 
less active than E,E-farnesol. However, the epoxide at the 10,11 posi-
tion (36, 1.7%) was still active, as were the 10-hydroxyl (37, 1.7%) and 
Table 5. Biological Activity of Farnesol Analogs with Sulfur Atoms at the 9 Position
Analog    Relative
Number  X =   IC50 (μM)  Activity
21  n-butyl  23.8  4.94
22  Isobutyl  44.3  2.64
23  tert-butyl   0.86
24  n-pentyl  66.8  1.75
25  Benzyl  68.9  1.72
26  Phenyl  79.2  1.47
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6-hydroxyl (38, 1.5%) analogs (Table 7). The 10,11 epoxide of farne-
sol is, of course, the reduced form of insect juvenile hormone III (39) 
which has a methyl ester at the C-1 position instead of the hydroxyl 
in farnesol. Thus, the QSM inactivity of juvenile hormone III (39) is ex-
pected from the inactivity of the corresponding methyl ester of farne-
sol (6, Table 2). Finally, in terms of designing a potential affinity column 
for farnesol binding proteins, the omega-hydroxy 9-thia compound 
(40, 0.1 %) was 49-fold less active than its nonhydroxylated parent 
compound (21, Table 5). Similarly, all other farnesol analogs with a 
terminal/ω-hydroxyl group were inactive (data not shown). Future 
studies will be directed toward the design of an affinity column for 
farnesol binding proteins. 
Table 6. Biological Activity of Farnesol Analogs Containing Heteroatoms at the 4 or 9 Positions
Analog    Relative
Number  X =    IC50 (μM)  Activity
29  CH2  24.4  4.80
17  S  79.1  1.47
30  Se  45.7  2.57a
32  O   0.07
33  O (with methyl branch   0.51
       added back at 3-position)
18  SCH2–b
34  OCH2–b
31  NCH2–b
 X =
35    0.96
a. Compound 30 was 33% E and 67% Z at the 6,7-double bond. If only the E isomer was ac-
tive, it would have a relative activity of 7.72.
b.  18, 31, and 34 have four carbons instead of three, between the head group hydroxyl and 
the heteroatom.
c. Compounds 35 and 22 are identical except that 35 has 9-O while 22 has 9-S.
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Discussion 
We have examined 40 natural and synthetic analogs of farnesol with 
regard to their ability to block germ tube formation in Candida albi-
cans. Twenty-two of the forty analogs exhibited QSM activity. Thus, 
farnesol itself is not a requisite for QSM activity; there is flexibility 
with regard to the head group (Table 2), double bonds (Table 3), chain 
length (Tables 3 and 4), and the presence of sulfur and selenium het-
eroatoms in the farnesyl backbone (Tables 4-6). All of our assays in-
volve adding analogs to cells programmed for GlcNAc-induced germ 
tube formation. Thus, if we assume that there is an intracellular tar-
get/receptor for farnesol, the exogenous farnesol must cross the cy-
toplasmic membrane and then bind to the target. Therefore, the ad-
ministered level of farnesol or farnesol analog may not reflect the 
actual intracellular concentration available to the receptor or target. 
As a corollary, a farnesol analog could be inactive either because it 
has difficulty crossing the membrane or difficulty binding to the tar-
get. For instance, it is reasonable to suppose that the dihydroxy ana-
log (40) and the analogs containing a basic nitrogen (7 and 31) might 
have difficulty crossing the cytoplasmic membrane. Our focus on a 
Table 7. Biological Activity of Hydroxy and Epoxide Analogs of Farnesol
Analog    Relative
Number   IC50 (μM)  Activity
1   1.2  100
9  2,3-epoxide   0.38
36  10,11-epoxidea  68.8  1.72
37  10-hydroxylb  68.5  1.72
38  6-hydroxylb  79.2  1.47
39  Juvenile Hormone III 0.16
40    0.10
a. Compound 36 is a modified (reduced) form of juvenile hormone III in which the carboxyl 
group has been reduced to a primary alcohol.
b. Hydroxyls were introduced as racemic mixtures at the 10 (37) and 6 position (38) by hy-
droboration of the 10–11 and 6–7 double bonds, respectively.
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putative farnesol binding protein is made with full realization that ex-
isting data do not yet prove the existence of farnesol binding pro-
teins in C. albicans. 
At present, virtually nothing is known about farnesol’s mode of ac-
tion in regulating fungal cell morphology. One of the purposes in ex-
amining this collection of farnesol analogs was to put constraints on 
the possible modes of action for farnesol. As a starting point, farnesol 
could bind to a specific receptor. This receptor could be either a fun-
gal analog of the nuclear FXR receptor found in most higher eukary-
otes [8, 9] or a different farnesolspecific receptor. However, a genomic 
search of S. cerevisiae and C. albicans failed to identify sequences sim-
ilar to mammalian FXR receptors. Thus, if activity is mediated through 
a farnesol receptor, it is likely to be of a type not previously observed. 
What can we infer about the farnesol binding pocket of the pu-
tative receptor? How are conformational space and topographi-
cal space related to molecular recognition? One approach to our 
structure- activity results is the linear approach based upon the three 
regions of farnesol which are altered: (i) The C, terminal hydroxyl 
group, (ii) the C1-C4 “head group” region, and (iii) the C9-C12 “tail” re-
gion. We have not yet analyzed enough analogs of the C5-C8 “mid-
chain” region to draw any useful conclusions. In this regard, with the 
exception of 30, the central double bond of all the analogs (equiv-
alent to the 6,7 double bond of farnesol) retained the E configura-
tion of the starting material (usually geranyl bromide or chloride). It 
is tempting to suggest that the 6,7 double bond is critical for activ-
ity because compounds 13 (E) and 14 (Z), differing at the 2,3 dou-
ble bond, had equivalent activities (Table 4). 
The terminal hydroxyl group proved almost invariant. Although 
farnesoic acid and the amide (2 and 3) displayed activity, functional 
groups of similar size (aldehyde, methyl ester) or hydrogen-bonding 
ability (amine) possessed no QSM activity. In this regard, the reduced 
activity observed [1] for nerolidol (3,7, 11-trimethyl-1,6,10-dodecatri-
ene-3-ol) could reflect either the altered regiochemistry or increased 
steric bulk of the head group relative to the C1 primary hydroxyl of 
farnesol. On the other hand, nerolidol differs from farnesol only in a 
1,3-allylic transposition of the hydroxyl and alkene groups, and it is 
possible that allylic isomerization to farnesol may be the source of the 
“activity” of nerolidol. 
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The rest of the head group region, however, proved fertile ground 
for analog development. A primary alcohol was retained as a fixed 
element in all designs. It is interesting to analyze the alkanol analogs 
based on the assumption that the role of the farnesol C1-C4 region is 
to hold the alcohol in a particular register relative to the remainder 
of the molecule. The three-carbon span in 27 may be too short to al-
low the alcohol to occupy the same space as in farnesol, whereas the 
four-carbon span in 28 can achieve a farnesol-like disposition through 
a low-energy extended conformation and the longer five-carbon span 
in 29 can adopt a similar overall shape through introduction of a sin-
gle gauche kink. As a corollary, the inactivity of 10 suggests that the 
presence of a C-3 methyl on the same five-carbon span prevents the 
assumption of a farnesol-like conformation. The subtlety of these in-
teractions is further illustrated by comparing removal of the 3-methyl 
group for the all-carbon molecules (10 versus 29, 11-fold increase in 
activity), the sulfur-containing analogs (15 versus 17, 5-fold decrease 
in activity), and oxygen-containing analogs (33 versus 32, 7-fold de-
crease in activity). 
The need for a tail region was clear from the complete lack of ac-
tivity of the shorter (C10) geraniol [1]. Similarly, the lack of activity [1] 
of the diterpene (C20) geranylgeraniol could represent “too much” tail 
in terms of poor fit into a receptor or excess hydrophobicity. Replace-
ment of the terminal 4-methyl-3-pentenyl unit of farnesol with an iso-
butyl ether (35) resulted in loss of activity, whereas the 10,11-epoxide 
(36) and the 10-hydroxyl (37) analogs retained activity. Similarly, the 
n-butyl and isobutyl thioethers (21 and 22) retained activity while the 
inactivity of a tert-butyl thioether (23) suggested intolerance for ste-
ric bulk in the C9-C10 region. 
A second approach to our structure-activity results is based on 
the implications of substituting heteroatoms into the farnesol back-
bone. Most of the analogs containing a thioether retained QSM ac-
tivity (Tables 4 and 5). The exact chain length did not appear to be 
a critical variable. Compare the activities of 27-29 (Table 3) and 16-
18 (Table 4). In the latter series, 16, 17, and 18 had two-, three-, and 
four-carbon spacers between the sulfur and the hydroxyl, respectively. 
We note three points of interest in activity comparisons among four 
pairs of molecules, 28 and 16, 29 and 17, 10 and 15, and 1 and 13/14, 
which are identical except for the replacement of CH2 by sulfur. First, 
for four compounds (13/14, 16, and 17) introduction of the sulfur 
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atom decreases QSM activity relative to the carbon-containing ana-
log, whereas 15 displays 16-fold greater activity than the nonsulfur 
analog. Second, the mixed disulfide (19) also retains activity (Table 4). 
Thus, we have a sequence of three active compounds (29, 17, and 19) 
with nearly equivalent chain lengths but containing zero, one, and two 
sulfurs, respectively. The final point of note is that compound 15 was 
one of only nine analogs tested (8-10, 20, and 36-39 were the oth-
ers) that possessed a chiral center. Compound 15 was prepared and 
assayed as a racemic mixture; it is likely that one of the two enantio-
mers would possess even greater activity. 
Thus, both the all-carbon alkanols (27-29) and the thiaalkanols (16-
18) retain significant activity. In theory, the corresponding O-ethers 
should combine the best features of the alkanols (similar C-O and 
C-C bond lengths) and the thiaalkanols (similar conformational pref-
erences). However, none of the O-ethers had activity (Table 6). This 
outcome may be due to the greater polarity of the ethers as well as 
to an intramolecular H bond between the O-ether and the C-1 alco-
hol. This explanation is supported by a comparison between the inac-
tive O-ether (32) and the highly active Se-ether (30). The results could 
also reflect the relative C-X bond lengths: C-Se > C-S > C-C > C-O. 
A third approach to our structure-activity results is based on the 
role of alkenes in providing conformational constraints on the farne-
sol backbone. The three trisubstituted alkene subunits of farnesol 
each impart significant conformational constraints on neighboring 
linkages. In particular, allylic strain from the methyl groups at C3, 
C7, and C11 precludes conformations which place the C1-O, C4-C5, or 
C8-C9 bonds into juxtaposition with the methyl branches. Similarly, 
1,2-strain disfavors conformations which juxtapose the C4-C5 or  C8-C9 
bonds with the C3 or C7 methyl branches, respectively. The impor-
tance of these alkene-induced conformational constraints may be re-
flected in the lack of activity of the 2,3-dihydrofarnesol (10) and the 
2,3,6,7,10,11-hexahydro (saturated) farnesol (12). At the same time, 
the results from the head and tail analogs demonstrate that neither 
the C2-C3 nor C10-C11 double bonds are required for activity; structur-
ally related thioethers retain activity (Tables 4 and 5). Given the jux-
taposition of the activity retained by the thioethers versus that lost 
by removal of the double bonds in compounds 10 and 12, one can 
imagine three possible roles for the alkene units of farnesol: (i) fit-
ting into a narrow cleft, (ii) precluding particular conformations and 
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thereby organizing the main chain into the proper conformation for 
binding, or (iii) providing electron density or van der Waals surface 
for a particular interaction with the receptor. 
Each of the ideas has attractive features, and of course, they are not 
mutually exclusive. The first idea of a narrow cleft cannot be endorsed 
or completely ruled out from our results. The epoxy (9) and cyclopro-
pane (8) analogs preserve much of the conformational constraints of 
the 2,3-alkene but significantly enlarge the cross-sectional area of the 
alkene. The 2,3 cyclopropane analog maintains activity, but the more 
polar 2,3 epoxide has lost activity (Table 3). The second idea in which 
each of three trisubstituted alkenes exerts significant conformational 
constraints on the surrounding region suggests an obvious role in 
providing bias toward particular conformers. This hypothesis is sup-
ported by our discovery that the QSM activity of commercial farne-
sols correlates closely with the fraction of the natural E,E-isomer (Table 
1). The third idea in which the alkene units provide needed electron 
density fits with the strong activity of the thioethers. Replacement of 
either the head (Table 4) or tail (Table 5) alkene with a straight chain 
thioether maintains QSM activity. However, the activity of analogs con-
taining linear methylene head groups (27–29) suggests that electron 
density in the form of an alkene or a thioether is not essential. Thus, 
in summary, the factors which seem necessary for farnesol’s QSM ac-
tivity and binding to a presumptive farnesol binding protein include: 
(i) a C-1 hydroxyl; (ii) a C-3 methyl group (but no larger); (iii) a hydro-
phobic tail; and (iv) the appropriate conformational constraints on 
backbone conformers as provided by the three, trisubstituted alkenes 
of farnesol. Factors which do not seem as critical include: (i) absolute 
chain length; (ii) the chemical structure of the C9-C12 hydrophobic tail; 
and (iii) the origin of the needed conformational constraints in the 
backbone. S and Se heteroatoms are permitted. 
Significance 
Farnesol is a quorum-sensing molecule in Candida albicans that acts 
to block the transition from yeasts to mycelia. It is widely agreed that 
this morphological transition is a critical feature of this organism’s 
pathogenicity. A further understanding of the action of farnesol on a 
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molecular level could lead to better control of this common human 
pathogen. To address this topic, we created a series of farnesol ana-
logs and examined their ability to inhibit mycelial development. Taken 
together, our results provide four major advancements to the under-
standing of the molecular action of farnesol. (1) Of the four possible 
geometric isomers of farnesol, only the E,E isomer possesses QSM ac-
tivity. (2) Structural analogs of farnesol that retain biological activity 
can be synthesized. In other words, farnesol itself is not essential for 
the activity seen in C. albicans. (3) Subtle changes in the structure of 
farnesol lead to significant changes in the activity. (4) These analogs 
indicate which parts of the molecule can be altered and still retain ac-
tivity and which are essential for activity. This information may help in 
the development of second generation farnesol analogs with useful 
pharmacokinetic properties. For instance, studies using cyclization to 
achieve conformational constraint seem indicated. However, even the 
most active of the analogs tested had only 7.3% of the activity of E,E-
farnesol, and thus they are unlikely to have any therapeutic potential 
as farnesol agonists in hosts infected by C. albicans. However, if farne-
sol does prove to be a virulence factor for C. albicans, these analogs 
may prove to be effective antagonists for farnesol. 
Experimental Procedures 
Strain and Chemicals 
Candida albicans A72 was obtained from Patrick Sullivan, University of 
Otago, Dunedin, New Zealand. A stock culture was grown in modified 
glucose-salts-biotin medium, washed in potassium phosphate buffer, 
and stored in the same buffer as previously described [1]. Commer-
cial mixed isomers farnesol (Acros Organics and Sigma), E,E-farnesol 
(Sigma), and farnesal (Pfaltz and Bauer, Waterbury, CT) were stored at 
–20°C with desiccant. Juvenile Hormone III, E,E-farnesyl bromide, and 
all-trans retinol (Sigma) were stored at –20°C. Our fresh farnesol sam-
ples were roughly ten times more active than those we had reported 
previously [1], probably because this time we were scrupulous to ex-
clude oxygen by resealing the pure farnesol oils under nitrogen and 
storing them with desiccation. 
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General Synthetic and Analytical Procedures 
General procedures for synthesis and characterization of substrates 
follow. Experimental procedures and characterization data for individ-
ual compounds are found in the accompanying appendix. All reagents 
and solvents were used as supplied commercially, except tetrahydrofu-
ran (THF; distilled from sodium/benzophenone), CH2CI2 (distilled from 
CaH2), hexamethylphosphoric triamide (HMPA; distilled from CaH2 and 
stored over 4 Å mol sieves), and N,N-dimethylformamide (DMF; stored 
over 4 Å sieves). Unless otherwise noted, reactions were run under a 
blanket of N2 in a round-bottom flask equipped with a magnetic stir-
rer. Except where noted, NMR spectra were taken as CDCI3 solutions at 
300 MHz (1H) or 75 MHz (13C). Infrared spectra were acquired on neat 
films on a ZrSe crystal. Purification of most compounds was based 
upon air-driven (2-5 psi) flash chromatography on 230-400 mesh sil-
ica; the solvent system employed is listed for each compound. Thin-
layer chromatography (TLC) employed silica (0.25 mm layer thick-
ness) on glass plates; detection was accomplished with a hand-held 
UV lamp, iodine vapor, 1% aqueous KMnO4 (alkenes), or charring with 
a solution of ceric sulfate and ammonium molybdate in 10% H2SO4 
(most compounds). Analytical and semipreparative HPLC employed 
0.5 × 25 cm and 2.1 × 25 cm silica columns, with detection by refrac-
tive index. Mass spectra were obtained at the Nebraska Center for 
Mass Spectrometry (Lincoln, NE). All prepared compounds were ho-
mogeneous by TLC, 1H NMR, and 13C NMR except for compound 30, 
which was 33% trans and 67% cis at the 6,7 double bond. 
Bioassays of Farnesol and Related Compounds 
The bioassays were performed in 25 ml Erlenmeyer flasks in a dif-
ferentiation medium consisting of 11 mM imidazole, pH 6.5, 3 mM 
MgSO4, 2.6 mM N-acetyl-D-glucosamine (GlcNAc) as the germ tube 
inducer, and either methanol (for a control) or a methanolic solution 
of the compound being tested. All solutions of farnesol in methanol 
were used immediately after preparation. Despite the fact that dilute 
aqueous solutions of farnesol can be stable for years [1], pure farne-
sol oils are highly susceptible to air oxidation resulting in modifica-
tion of the 10,11-alkene unit. Our assays of the 10,11-epoxide and the 
10-hydroxyl compounds (Table 7) confirm that oxidative modification 
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of the 10,11-alkene is accompanied by a dramatic decrease in QSM 
activity. Prior to analysis, all compounds were dried, stored at 4°C for 
no more than 24 hr, and resuspended as a 25 mM stock solution in 
100% methanol immediately before use. The final concentration of 
methanol in the bioassays was ≤1 %. All compounds were tested at 10, 
50, and 100 μM for their ability to block germ tube formation. These 
concentrations are well below the 250-300 μM levels at which farne-
sol itself does not impact the growth rate of C. albicans [1, 3]. Flasks 
were preincubated at 37°C for 20 min and then inoculated to 5 × 106 
cells/ml of C. albicans A72. Flasks were incubated at 37°C for 4 hr with 
shaking at 250 rpm on a New Brunswick Scientific Co. G2 shaker. Af-
ter 4 hr, cells were examined by phase-contrast microscopy. At least 
100 cells were counted for every flask and analyzed for percent germ 
tube formation. Compounds which exhibit farnesol-like activity cause 
a shift from germ tubes to actively budding yeasts. Previous stud-
ies indicated that any lethal compounds or lethal concentrations in-
stead gave phase dark, undifferentiated cells. None of analogs tested 
 exhibited toxicity at concentrations up to 100 μM. 
Activity Calculations 
Two measures of analog activity were employed. In the first, we com-
pared the concentrations of farnesol and the analog necessary to 
lower the percent germ tubes formed to 50%. An analog is consid-
ered to be active if it was capable of reducing germ tube formation 
by 50% at the highest concentration tested. For inactive analogs, we 
used an exponential decay function to model the activities of the 
farnesol standard and the farnesol analogs according to the function 
G = G0 × e(b×c), where G represents the percentage of germ tubes, C, 
the concentration of sample in the assay, G0, the percentage of germ 
tubes when C = 0, and b, the steepness of the decay. At zero concen-
tration, 95%-99% mycelia were observed for all samples, and there-
fore, G0 was fixed at 95. This allowed a single parameter, b, to be de-
termined by the least-squares method using the Maple V program 
(Waterloo Maple, Waterloo, CAl. A commercial sample of E,E-farne-
sol (Sigma) was chosen as the standard. The percentage activity for 
each analog was then determined by the ratio of the calculated b val-
ues from the regression algorithm. Results are presented in the tables 
as “relative activity.” 
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Supplemental Data — Experimental procedures and characterization (TLC, 1H and 
13C NMR, and IR) for compounds 7, 11, 13-19, 21-23, 25, 27-35, and 37-38 can be 
found at http://www.chembiol.com/cgi/content/full/10/8/743/DC1 ; references to 
preparations of known compounds (3, 6, 8-10, 12, 26, and 36) are also provided. 
Acknowledgments — This work was supported by grants from the National Sci-
ence Foundation (MCB-0110999) and the University of Nebraska Tobacco Settle-
ment Biomedical Research Enhancement Fund. We thank Sara Basiaga for assistance 
with GC/MS and Bruce D. Hammock for pointing out the tendency of farnesol oils 
to undergo air oxidation.  
References 
1. Hornby, J.M., Jensen, E.C., Lisec, A.D., Tasto, J.J., Jahnke, B., Shoemaker, R., 
Dussault, P., and Nickerson, K.W. (2001). Quorum sensing in the dimorphic 
fungus Candida albicans is mediated by farnesol. Appl. Environ. Microbiol. 67, 
2982-2992. 
2. Fuqua, W.C., Winans, S.C., and Greenberg, E.P. (1994). Quorum sensing in 
bacteria: the Lux R-Lux I family of cell density-responsive transcriptional 
regulators. J. Bacteriol. 176, 269-275. 
3. Ramage, G., Saville, S.P., Wickes, B.L., and Lopez-Ribot, J.L. (2002). Inhibition of 
Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. 
Appl. Environ. Microbiol. 68, 5459-5463. 
4. Lo, H.J., Kohler, J.R., DiDomenico, B., Loebenberg, D., Cacciapuoti, A., and 
Fink, G.R. (1997). Nonfilamentous C. albicans mutants are avirulent. Cell 90, 
939-949. 
5. Vaidya, S., Bostedor, R., Kurtz, M.M., Bergstrom, J.D., and Bansal, V.S. (1998). 
Massive production of farnesol-derived dicarboxylic acids in mice treated with 
the squalene synthase inhibitor zaragozic acid A. Arch. Biochem. Biophys. 355, 
84-92. 
6. Oh, K.-B., Miyazawa, H., Naito, T., and Matsuoka, H. (2001). Purification and 
characterization of an autoregulatory substance capable of regulating the 
morphological transition in Candida albicans. Proc. Natl. Acad. Sci. USA 98, 
4664-4668.  
7. Matsuoka, H., and Oh, K-B. (2001). Bio Giken K.K., August, 2001. Compound 
to regulate the morphological transition of dimorphic Candida. United States 
Patent Number 6,271,267. 
8. Edwards, P.A., and Ericsson, J. (1999). Sterols and isoprenoids: signaling 
molecules derived from the cholesterol biosynthetic pathway. Annu. Rev. 
Biochem. 68, 157-185. 
9. Forman, B.M., Goode, E., Chen, J., Oro, A.E., Bradley, D.J., Perlmann, T., Noonan, 
D.J., Burka, L.T., McMorris, T., Lamph, W.W., et al. (1995). Indentification of a 
nuclear receptor that is activated by farnesol metabolites. Cell 81, 687-693.   
APPENDIX/SUPPORTING INFORMATION 
Known Farnesol analogs:  Eight of the farnesol analogs used in this work have been 
synthesized and characterized previously. They are: compound 3, the farnesoyl amide, 
see appendix reference #1 below; compound 6, the methyl ester of farnesoic acid, ref #2; 
compound 8,  2,3-cyclopropane, ref #3; compound 9, 2,3-epoxide, ref #4;  compound 10, 
2,3-dihydro, ref #5; compound 12, perhydro, ref #6; compound 26, 8-phenylthiogeraniol, 
ref #7;  and compound 36, 10,11-epoxide, ref #8.  In each case, the identities and purities 
of the previously reported compounds were determined by 1H and 13C NMR.  The other 
farnesol analogs described below had not been previously reported.  Compounds 1,2,4,5, 
and 39 were purchased commercially. 
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Previously unreported farnesol analogs 
Farnesyl amine  [(2E,6E)-3,7,11-trimethyldodecadienylamine] (compound 7): To the 
solution of N-farnesyl trifluoroacetamide (0.7mmol) in THF (5mL) was added 6N NaOH 
(3mmol).  The solution was refluxed for 5 h. and then solvent was removed under 
reduced pressure.  The residue was diluted with water and extracted with CH2Cl2. The 
organic layer was washed with water, dried over Na2SO4 and evaporated in vacuo to give 
farnesylamine (95%): Rf=0.5 (10% NH3-saturated MeOH in CH2Cl2); 1H δ 1.33(s, 2H), 
1.59(s, 6H), 1.62(s, 3H), 1.67(s, 3H), 1.96-2.10(m, 8H), 3.26(d, 2H, 6.9Hz), 5.09(m, 2H), 
5.25(m, 1H); 13C NMR δ 15.96, 16.05, 17.63, 25.64, 26.40, 39.51, 39.61, 39.67, 124.00, 
124.32, 125.87, 131.26, 135.13, 136.35; IR 2920, 1742,1563, 1440, 1291, 815 cm-1. 
(2E,6E)-3,7,11-trimethyldodeca-2,6-dienol (compound 11): To a solution of 1-bromo-
3-methylbutane (10mmol) in dry THF (25mL) was  added Mg (9mmol, turnings) and a 
crystal of I2. The reaction was heated to reflux for 2 h (complete consumption of Mg), 
cooled to -78°C and diluted with HMPA (3.5mL).  A solution of (E)-8-bromogeranyl 
acetate (1mmol) in THF (1mL) was added and the reaction was kept at -78°C for 2 h.  
The reaction was then brought to room temperature and stirred for 10 h. Work-up as 
before, followed by flash chromatography (20% EA/hex) afforded 10,11-dihydrofarnesol 
in 60% yield: Rf=0.3 (20% EA/hex); 1H NMR δ 0.87(d, 6H, 7.2Hz), 1.12(m, 2H), 
1.37(m, 2H), 1.52(m, 1H), 1.57(s, 3H), 1.67(s, 3H), 1.93(t, 2H, 7.5Hz), 2.05(m, 4H), 
4.14(d, 2H, 6.9Hz), 5.08(m, 1H), 5.41(m, 1H); 13C NMR δ 15.84, 16.22, 22.60, 25.70, 
26.24, 27.84, 38.56, 39.55, 39.86, 59.33, 123.33, 123.45, 135.71, 139.71. 
(2E)-4-thiafarnesol[(2E,6E)-3,7,11-Trimethyl-4-thia-2,6,10-dodecatrienol] 
(compound 13) and (2Z)-4-thiafarnesol) [(2Z,6E)-3,7,11-Trimethyl-4-thia-2,6,10-
dodecatrienol] (compound 14): To a solution of (E)-geranyl thioacetate (3.7mmol) in 
THF (15mL) was added MeONa (11.1mmol in 3mL of MeOH). After 30min, the reaction 
was cooled to -78°C and ethyl 2-butynoate (4.44mol) was added drop wise via syringe. 
After 10 h, the reaction was worked up as for the thioethers (e.g. compound 15) and 
concentrated to furnish the alkenoate thioether as a crude oil, which was used without 
further purification.  
The oil was dissolved in THF (2ml), cooled down to -78°C and subjected to the 
diisobutyl aluminum hydride (DIBAL) reduction (10mmol of 1.5M solution in toluene).  
Following a standard work-up, the Z and E thioenol isomers were separated by flash 
chromatography with 20% EA/hex to furnish 0.511g (50%) of the E-isomer (compound 
13) and 0.128g (12%) of the Z isomer (compound 14). 
(2E,6E)-3,7,11-trimethyl-4-thiadodeca-2,6,10-trienol (compound 13):  Rf=0.3 (20% 
EA/hex); 1H  δ 1.42(s, 1H), 1.59(s, 3H), 1.68(s, 6H), 1.93(s, 3H), 2.03(m, 4H), 3.36(d, 
2H, 7.2Hz), 4.19(d, 2H, 7.2 ), 5.07(m, 1H), 5.25(m, 1H), 5.43(m, 1H); 13C δ 16.11, 
17.63, 17.88, 25.61, 26.37, 29.39, 39.47, 59.22, 118.13, 120.72, 123.81, 131.67, 136.25, 
140.17; IR 3347, 2952, 2929, 2871, 1454, 1060 cm-1. 
(2Z,6E)-3,7,11-Trimethyl-4-thiadodeca-2,6,10-trienol (compound 14): Rf=0.4 (20% 
EA/hex); 1H NMR δ 1.25(s, 1H), 1.59(s, 3H), 1.66(s, 6H), 2.04(m, 7H), 3.35(d, 2H, 
7.5Hz), 4.27(d, 2H, 6.9Hz), 5.06(m, 1H), 5.21(m, 1H), 5.75(m, 1H); 13C δ 16.06, 17.65, 
23.83, 25.62, 26.37, 29.04, 39.47, 59.97, 119.89, 123.79, 129.34, 131.68, 134.08, 139.34; 
IR 3321, 2917, 1629, 1438, 1375, 1224, 1079, 1001, 836 cm-1. 
Preparation of thioethers (compounds 15, 16, 17 and 18): Into a solution of 
mercaptoalcohol (2mmol) in dry tetrahydrofuran (THF)(20mL) was added NaOH 
(2mmol). The stirred solution was cooled to -78°C and (E)-geranyl chloride (1mmol) was 
added via syringe. The reaction was allowed to warm to room temperature, and, after 12 
h, concentrated under reduced pressure.  The residue was diluted with water and 
extracted with 20% ethyl acetate/hexane (EA/hex). The organic layer was washed with 
water, dried over Na2SO4 and concentrated under reduced pressure. The resulting oil was 
purified by flash chromatography (10% EA/hex).   
(E)-3,7,11-Trimethyl-4-thiododeca-6,10-dienol (compound 15): (95% yield); Rf=0.4 
(20% EA/hex); 1H δ 1.30(d, 3H, 6.9Hz), 1.58(s, 3H), 1.66(s, 6H), 2.04(m, 5H), 2.87(m, 
1H), 3.18(d, 2H, 7.5Hz), 3.76(m, 2H), 5.07(m, 1H), 5.24(m, 1H); 13C δ 15.99, 17.62, 
21.93, 25.61, 26.40, 28.01, 36.90, 39.10, 39.52, 60.86, 120.42, 123.89, 131.61, 138.72; 
IR 3365, 2920, 1450, 1375, 1045, 994, 846 cm-1. 
(E)-6,10-Dimethyl-3-undeca-5,9-dienol (compound 16): (93% yield); Rf=0.4 (20% 
EA/hex); 1H δ 1.59(s, 3H), 1.64(s, 3H), 1.67(s, 3H), 2.05(m, 4H), 2.24(s, 1H), 2.67(t, 2H, 
6Hz), 3.15(d, 2H, 7.8Hz ), 3.69(q, 2H, 5.7Hz), 5.06(m, 1H), 5.22(m, 1H); 13C δ 15.99, 
17.65, 25.64, 26.37, 28.72, 34.08, 39.54, 60.28, 120.20, 123.84, 131.71, 139.28; IR 3375, 
2914, 1742, 1440, 1378, 1225, 1045, 830 cm-1. 
(E)-7,11-Dimethyl-4-thiadodeca-6,10-dienol (compound 17):  (84% yield); Rf=0.4 
(20% EA/hex); 1H  δ 1.60(s, 3H), 1.65(s, 3H), 1.67(s, 3H), 1.76(s, 1H), 1.83(m, 2H), 
2.05(m, 4H), 2.58(t, 2H, 7.2Hz), 3.16(d, 2H, 7.8Hz), 3.74(t, 2H, 5.7Hz), 5.08(m, 1H), 
5.23(m, 1H); 13C δ 16.02, 17.65, 25.64, 26.42, 27.73, 29.26, 31.87, 39.55, 61.98, 120.34, 
123.89, 131.65, 138.88; IR 3358, 2919, 1739, 1442, 1375, 1217, 1042 cm-1. 
(E)-8,12-Dimethyl-5-thiotrideca-7,11-dienol (compound 18): (85% yield);  Rf=0.4 
(20% EA/hex); 1H δ 1.51(s, 1H), 1.60-1.67(m, 13H), 2.04(m, 4H), 2.49(m, 2H), 3.14(d, 
2H, 7.8Hz), 3.65(s, 2H), 5.07(m, 1H), 5.22(m, 1H); 13C δ 15.97, 17.65, 25.64, 25.84, 
26.42, 29.22, 30.67, 31.93, 39.55, 62.37, 120.53, 123.91, 131.59, 138.59;  IR 3357, 2923, 
1733, 1443, 1374, 1224, 1053 cm-1. 
(E)-7,11-dimethyl-3,4-dithiododeca-6,10-dienol (compound 19):  To a solution of 
geranyl thio acetate (0.5mmol) in 50:50 THF/MeOH was added NaOH (10mmol) and the 
mixture was stirred for 30 min. Following addition of 2-mercaptoethanol (5mmol), the 
solution was exposed to air for 10 h. Standard work-up followed by purification by flash 
chromatography with 20% EA/hex afforded the mixed disulfide in 28mg (6%):  Rf=0.5 
(hexane); 1H NMR δ 1.60(s, 3H), 1.68(s, 3H), 1.70(s, 3H), 2.06(m, 5H), 2.85(t, 2H, 
5.7Hz), 3.42(d, 2H, 8.1Hz), 3.88(quartet, 2H, 5.7Hz), 5.08(m, 1H), 5.28(m, 1H); 13C 
NMR δ 16.31, 17.66, 25.65, 26.31, 37.09, 39.61, 41.30, 60.28, 118.63, 123.75, 131.80, 
141.48. 
9-thia analogs (compounds 21-23 and 35) 
(E)-8-hydroxygeranyl acetate: A solution of (E)-geranyl acetate (46mmol) and SeO2 
(41mmol) in ethanol (70mL) was refluxed for 3h and then allowed to cool after which 
NaBH4 (26mmol) was added. After 30 min, the reaction was filtered through a paper 
filter and solvent was removed under reduced pressure. Work-up and chromatography 
(20% EA/Hex) as above furnished 41% of (E)-8-hydroxygeranyl acetate along with 20% 
of recovered starting material: Rf=0.4 (50% EA/hex); 1H NMR δ 1.61(s, 3H), 1.66(s, 3H), 
2.00-2.11(m, 8H), 3.93(s, 2H), 4.53(d, 2H, 6.9Hz), 5.30(m, 2H); 13C δ 13.5, 16.3, 20.9, 
25.5, 38.9, 61.3, 68.3, 118.5, 124.9, 135.1, 141.6, 171.1. 
(E)-8-bromogeranyl acetate: Into a -78°C solution of (E)-8-hydroxygeranyl acetate 
(2mmol) and pyridine (2mmol) in THF (15mL) was added PBr3 (1mmol). The reaction 
was allowed to warm to room temperature and stirred for 3 h.  The reaction was then 
quenched with 0°C sat. aq. NaHCO3 and extracted with 20% EA/hex. The crude allyl 
bromide (estimated yield of 90%) was used directly for subsequent reactions.  
9-thiafarnesol analogs (compounds 21, 22, and 23): To a solution of thiol (2.5mmol) in 
THF (7mL) was added NaOH (1mmol) followed by (E)-8-bromogeranyl acetate 
(0.5mmol in 0.5mL of THF). The mixture was stirred for 10 h whereupon 6N NaOH 
(0.5mL) and H2O (3mL) were added. After stirring for 30 min., the reaction was worked 
up as for other thioethers (e.g. compound 15). The oil was purified by flash 
chromatography with 20% EA/hex to furnish the thioether.  
(2E,6E)-3,7-Dimethyl-9-thiatridecadienol (compound 21): (89% yield); Rf=0.3 (20% 
EA/hex); 1H NMR (500Mz) δ 0.90(t, 3H, 7.5Hz), 1.27(s, 1H), 1.38(m, 2H), 1.52(m, 2H,), 
1.67(s, 3H), 1.70(s, 3H), 2.06(m, 2H), 2.16(m, 2H), 2.37(t, 2H, 7.5Hz), 3.07(s, 2H), 
4.14(d, 2H, 6.5Hz), 5.22(m, 1H), 5.41(m, 1H); 13C NMR (125Mz) δ 13.70, 14.92, 16.17, 
22.02, 26.28, 30.40, 30.89, 31.43, 39.28, 41.27, 59.31, 123.64, 127.26, 131.48, 139.20; 
IR 3336, 2920, 1445, 1219, 1004 cm-1. 
(2E,6E)-3,7,11-Trimethyl-9-thiadodecadienol (compound 22): (86% yield); Rf=0.3 
(20% EA/hex); 1H NMR(500Mz) δ 0.96(d, 6H, 8.5Hz), 1.27(s, 1H), 1.66-1.76(m, 7H), 
2.07(m, 2H), 2.15(m, 2H), 2.25(d, 2H, 8.5Hz), 3.05(s, 2H), 4.15(d, 2H, 5Hz), 5.21(m, 
1H), 5.41(m, 1H); 13C NMR(125Mz) δ 14.92, 16.19, 22.05, 26.29, 28.28, 39.29, 39.90, 
41.80, 59.33, 123.64, 127.34, 131.55, 139.23. 
(2E,6E)-3,7,10,10-Tetramethyl-9-thiaundecadienol (compound 23): (91% yield); 
Rf=0.4 (20% EA/hex); 1H NMR δ 1.32(s, 9H), 1.60(s, 1H), 1.66(s, 3H), 1.72(s, 3H), 
2.06(m, 2H), 2.13(m, 2H), 3.17(s, 2H), 4.14(d, 2H, 9Hz), 5.54(m, 1H), 5.41(m, 1H); 13C 
δ 15.52, 16.13, 26.24, 30.85, 38.27, 38.98, 42.35, 59.33, 123. 76, 127.13, 132.10, 139.16. 
(E,E)-3,7,11-Trimethyl-9-oxadodeca-2.6-dienol (compound 35): (92% yield); To the 
suspension of NaH (3mmol, 60% dispersion in mineral oil) in THF (10mL) was added 
isobutyl alcohol (10mmol) followed by (E)-8-bromogeranyl acetate (0.5mmol in 0.5mL 
of THF).  After 10 h, 6N NaOH (0.5mL) and H2O (3mL) were added and the reaction 
was stirred for 30 min.  Work-up as before furnished 0.104g (92%) of the ether as an oil:  
Rf=0.3 (20% EA/hex);  1H NMR δ 0.91(d, 6H, 6Hz), 1.23(s, 1H), 1.64(s, 3H), 1.69(s, 
3H), 1.86(m, 1H), 2.03-2.23(m, 4H), 3.12(d, 2H, 6Hz), 3.83(s, 2H), 4.15(d, 2H, 6.4Hz), 
5.34(m, 2H); 13C NMR δ 14.5, 17.0, 20.1, 26.7, 29.2, 39.8, 60.1, 77.4, 77.6, 124.4, 127.6, 
133.8, 140.0. IR 3375, 2920, 1460, 1086, 1004 cm-1. 
Alkanol analogs (compounds 27-29).  
(E)-5,9-Dimethyldeca-4,8-dienol (compound 27): Compound 27 was prepared from 
(E)-geranyl chloride and vinyl magnesium bromide by a two step procedure similar to 
that used for compound 19. The initial product was (E)-5,9-dimethyldeca-1,4,8-triene  (1-
24): Rf=0.9 (hexane); 1H NMR δ 1.62(s, 6H), 1.7(s, 3H), 2.76(t, 2H, 6.6), 4.94-5.18(m, 
4H), 5.81(m, 1H).  Hydroboration of the triene as described above furnished compound 
20 in 57% (two steps): Rf=0.3 (20% EA/hex); 1H δ 1.48(s, 1H), 1.57-1.67 (m, 11H), 
2.06(m, 6H), 3.63(t, 2H, 6.6Hz), 5.12(m, 2H); 13C NMR δ 15.91, 17.63, 24.23, 25.65, 
26.61, 32.70, 39.67, 62.68, 123.73, 124.23, 131.40, 135.77;  IR 3339, 2919,1736, 1450, 
1214, 1050 cm-1. 
(E)-6,10-Dimethylundeca-5,9-dienol (compound 28): (E)-geranyl chloride (3mmol) 
was added drop-wise via syringe into a -78°C solution of allyl magnesium chloride 
(7.5mmol, 2M solution in THF) and hexamethylphosphoric triamide (HMPA)(1mL) in 
THF (6mL). The reaction was allowed to warm to room temperature, and after 12 h, 
quenched with water. The pentane extract was washed with water, dried over Na2SO4 and 
concentrated by evaporation at normal pressure. The resulting oil was purified by flash 
chromatography with pentane to furnish (E)-6,10-dimethylundeca-1,5,9-triene (1-22) in 
67% yield: Rf=0.9 (hexane);  1H 1.62(s, 6H), 1.70(s, 3H), 1.99-2.12(m, 8H), 4.94-5.18(m, 
4H), 5.84(m, 1H). 
9-BBN (9-borabicyclononane) (2mmol, 0.5M solution in THF) was added to a 
solution of the triene (estimated 2mmol) in THF (15mL). After 5 h, the reaction was 
quenched by the successive addition of ethanol (2mL), 6N aq. NaOH (3mmol), and 30% 
H2O2 (4mmol). The mixture was diluted with water and extracted with 20% EA/hex. 
Work-up as before and purification by flash chromatography with 20% EA/hex furnished 
the alcohol in 53% yield over two steps.  Rf=0.4 (20% EA/hex); 1H NMR δ 1.40(m, 3H), 
1.59(m, 8H), 1.60(s, 6H), 1.68(s, 3H), 2.00(m, 6H), 3.64(t, 2H, 6.6Hz), 5.10(m, 2H); 13C 
δ 15.96, 17.65, 25.67, 25.90, 26.67, 27.55, 32.32, 39.70, 64.97, 124.23, 124.32, 131.30, 
135.29;  IR 3331, 2922, 2922, 1443, 1373, 1058 cm-1. 
(E)-7,11-Dimethyldodeca-6,10-dienol (compound 29):  A solution of 4-bromo-1-
butene (30mmol) in THF (17mL) was refluxed for 3 h over Mg (30 mmol) until the 
turnings were consumed.  The resulting solution was cooled to -78°C and diluted with 
HMPA (2.5mL).  Addition of (E)-geranyl bromide (3mmol), followed by work-up and 
purification as above afforded (E)-6,10-dimethyldeca-1,6,10-triene (1-30): Rf=0.9 
(hexane); 1H δ 1.43(m, 2H), 1.60(s, 6H), 1.69(s, 3H), 2.04(m, 6H), 4.92-5.13(m, 4H), 
5.81(m, 1H).  
Hydroboration as before furnished dienol compound 29 in 42% yield over two 
steps: Rf=0.5 (20% EA/hex); 1H δ 1.31(s, 1H), 1.35(m, 4H), 1.59(m, 8H), 1.68(s, 3H), 
2.00(m, 6H), 3.63(t, 2H, 6.3Hz), 5.11(m, 2H); 13C δ 15.94, 17.65, 25.33, 25.67, 26.72, 
27.79, 29.60, 32.71, 39.70, 63.03, 124.35, 124.43, 131.26, 135.0;  IR 3335, 2926, 2852, 
1447, 1377, 1054 cm-1. 
7,11-Dimethyl-4-selenadodeca-6,10-dienol (compound 30): To a -78°C solution of 
KSeCN (2.2mmol) in THF (10mL) was added the tetrahydropyranyl ether of 3-
bromopropanol (2mmol). After stirring for 10h, the reaction was diluted with water and 
extracted with pentane. The organic layer was washed with water, dried over sodium 
sulfate and evaporated in vacuo to give the selenocyanate which was used without further 
purification.  Into a -78°C THF solution of the selenocyanate was successively added 
NaBH4 (4mmol), ethanol (1mL) and (E)-geranyl chloride (1mmol). The reaction was 
warmed to room temperature and stirred for 10 h.  Following work-up as before, the 
crude residue was treated with 100mg of pyridinium p-toluenesulfonate in 5ml MeOH for 
7 h. Concentration, followed by flash chromatography with 20% EA/hex, afforded the 
selenoether (0.215 g, 78%) as a 32:67 mixture of Z:E isomers according to GC/MS 
(retention times 16.98:17.28 min.): Rf=0.4 (20% EA/hex); 1H (mixture of E and Z 
isomers) δ 1.57-1.71(m, 9H), 1.89(p, 2H, 6.6Hz), 2.04(m, 5H), 2.58(m, 2H), 3.20(d, 2H, 
8.4Hz), 3.69(t, 2H, 6.3Hz), 5.05(m, 1H), 5.31(m, 1H); 13C NMR(mixture of E and Z 
isomers) δ 15.77, 17.59, 19.44, 19.83, 20.70, 23.25, 25.58, 26.41, 26.49, 31.61, 32.92, 
39.41, 39.51, 62.37, 62.43, 120.93, 121.58, 123.79, 123.85, 131.55, 131.84, 138.29, 
138.38:  FAB-MS: M/Z(M+Li)+=283.1 
(E)-8,12-Dimethyl-5-azatrideca-7,11-dienol (compound 31): To a solution of 4-
aminobutanol (2mmol) in THF (15mL) was added NaHCO3 (5mmol) and (E)-geranyl 
bromide (1mmol). After stirring for 10 h., the reaction mixture was found to still contain 
unreacted geranyl bromide and was heated to reflux for 2 h.  Work-up as before followed 
by flash chromatography with a 10% solution of sat. NH3/MeOH in CH2Cl2 furnished 
0.025g (11%) of the desired secondary amine along with 0.1516g (42%) of the tertiary 
amine byproduct.  Rf=0.2 (10% of sat. NH3/MeOH in CH2Cl2); 1H δ 1.58-1.66(m, 13H), 
2.02(m, 4H), 2.64(t, 2H, 5.7Hz), 3.23(d, 2H, 6.9Hz), 3.33(s, 3H), 3.57(t, 2H, 4.5Hz), 
5.06(m, 1H), 5.24(m, 1H); 13C δ 16.19, 17.65, 25.64, 26.42, 28.53, 32.39, 39.57, 46.49, 
48.79, 62.46, 121.35, 123.95, 131.58, 138.94. 
Preparation of ethers (compounds 32 and 34): The diol (7mmol) was added to a stirred 
suspension of NaH (3mmol as 60% dispersion in mineral oil) in distilled THF (20mL).  
The mixture was stirred for 20 minutes.  (E)-geranyl bromide (1mmol) was added drop 
wise via syringe and the reaction was refluxed for 4 h. Work-up as above followed by 
flash chromatography (20% EA/hex) furnished the ether. 
(E)-7,11-Dimethyl-4-oxadodeca-6,10-dienol (compound 32): (72% yield); Rf=0.3 
(20% EA/hex); 1H δ 1.59(s, 3H), 1.65(s, 3H), 1.67(s, 3H), 1.82(pentet, 2H, 5.7Hz), 
2.04(m, 4H), 2.52(s, 1H), 3.60(t, 2H, 5.7Hz), 3.76(t, 2H, 5.4Hz), 3.98(d, 2H, 6.9Hz), 
5.07(m, 1H), 5.32(m, 1H); 13C δ 16.38, 17.62, 25.62, 26.28, 32.03, 39.51, 62.01, 67.54, 
69.21, 120.59, 123.87, 131.64, 140.34. 
(E)-8,12-Dimethyl-5-oxatrideca-7,11-dienol (compound 34): (76% yield); Rf=0.3 
(20% EA/hex);  1H δ 1.59(s, 3H), 1.67(m, 10H), 2.04(m, 4H), 2.58(s, 1H), 3.45(t, 2H, 
6Hz), 3.62(d, 2H, 5.4Hz), 3.98(d, 2H, 6.6Hz), 5.08(m, 1H), 5.33(m, 1H); 13C δ 16.37, 
17.62, 25.62, 26.31, 26.93, 30.34, 39.54, 62.68, 6729, 70.00, 120.52, 123.91, 131.61, 
140.33; IR 3396, 2920, 2858, 1445, 1373, 1102, 1061 cm-1. 
(E)-3,7,11-trimethyl-4-oxydodeca-6,10-dienol (compound 33):  A suspension of NaH 
(4.5mmol, 60% dispersion in mineral oil) was washed with hexane (2 x 0.3mL each), 
after which was added 3-butene-2-ol (4.5mmol) in 15mL of dry THF followed by  (E)-
geranyl bromide (1.5mmol).   The reaction was heated to reflux for 10h and then cooled. 
Solvent was removed at the reduced pressure, and the residue was diluted with water.  
The pentane extract was dried with Na2SO4 and evaporated at normal pressure to give a 
crude oil. Without further purification the crude material was dissolved in THF (5mL) 
and 9-BBN (9-borabicyclononane, 1.5mmol) was added. After 10 h., the reaction was 
quenched by the successive addition of ethanol (2mL), 6N NaOH (3mmol), and 30% 
H2O2 (4mmol). Following work-up as for compound 26, chromatography (20% EA/Hex)  
furnished the ether in 84% yield over two steps: Rf=0.3 (20% EA/hex);  1H NMR δ 
1.18(d, 3H, 6Hz), 1.59(s, 3H), 1.66-1.77(m, 8H), 2.04(m, 4H), 2.81(s, 1H), 3.75(m, 3H), 
3.93(m, 1H), 4.08(m, 1H), 5.07(m, 1H), 5.32(m, 1H); 13C δ 16.37, 17.63, 19.45, 25.64, 
26.29, 38.64, 39.52, 61.22, 64.74, 74.67, 120.84, 123.89, 131.65, 140.24;  IR 3411, 2925, 
1454, 1050 cm-1. 
(2E,6E)-3,7,11-trimethyldodecadiene-1,10-diol and (2E)-3,7,11-trimethyldodeca-
2,10-diene-1,6-diol (compounds 37 and 38): Into a solution of farnesol (1mmol) in THF 
(10mL) was added 9-BBN (9-borabicyclononane, 2mmol). The reaction was stirred for 
10 h and then quenched by the successive addition of ethanol (2mL), 6N NaOH (3mmol), 
and 30% H2O2 (4mmol). The resulting mixture was readily separated by flash 
chromatography (50% EA/hex) to afford 90% of recovered farnesol, 0.096g of 10-
hydroxyfarnesol and 0.144g of 6-hydroxyfarnesol.  
(2E,6E)-3,7,11-Trimethyldodecadiene-1,10-diol (compound 37): Rf=0.5 (50% 
EA/hex);  1H NMR δ 0.89(d, 6H, 6.6Hz), 1.47-1..66(m, 9H), 2.03-2.19(m, 6H), 3.35(m, 
1H), 4.10(d, 2H, 6.9Hz), 5.16(m, 1H), 5.39(m, 1H); 13C NMR δ15.76, 17.34, 18.67, 
25.64, 30.88, 31.23, 33.53, 36.69, 39.23, 59.20, 76.85, 124.24. 124.78, 135.96, 138.74; 
IR 3334, 2920, 1670, 1445, 1378, 999 cm-1.  FAB-MS: M/Z(M+Li)+=247.2. 
(2E)-3,7,11-Trimethyldodeca-2,10-diene-1,6-diol (compound 38):  Rf=0.4 (20% 
EA/hex);  1H NMR δ 0.89(d, 3H, 6.6Hz), 1.24(m, 2H), 1.51(m, 2H), 1.59(s, 3H), 1.68(m, 
6H), 1.35-2.28(m, 5H), 3.44(m, 1H), 4.14(d, 2H, 6.9Hz), 5.09(m, 1H), 5.44(m, 1H); 13C 
NMR δ 15.04, 16.24, 17.63, 25.64, 25.68, 31.14, 32.04, 36.16, 38.45, 59.26, 75.59, 
123.59, 124.55, 131.51, 139.74;  IR 3339, 2920, 2366, 2366, 1455, 1383, 999 cm-1. FAB-
MS: M/Z(M+Li)+=247.2. 
 
